乙肝抗病毒治疗进展-培训课件.pptVIP

* * * * * * * * * * * * * * * * * Patient 2068 stopped LAM on 17-Sep-01 (Week 28). Lamivudine was added to ADV on 24-Dec-02 (Week96). * N236T mutant HBV displays reduced susceptibility to adefovir but remains susceptible to lamivudine in vitro A181V mutant HBV confers 2 to 3-fold reduced susceptibility to adefovir. The clinical relevant cut-off value will be further evaluated. * N236T mutant HBV displays reduced susceptibility to adefovir but remains susceptible to lamivudine in vitro A181V mutant HBV confers 2 to 3-fold reduced susceptibility to adefovir. The clinical re